UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 553

Sortiert nach

1. Cardiovascular Disease

Nihon Naika Gakkai zasshi, 2012, Vol.101 (5), p.1272-1277

2012

Volltextzugriff (PDF)

1. Cardiovascular Disease

Nihon Naika Gakkai Zasshi, 2012, Vol.101(5), pp.1272-1277

2012

Volltextzugriff (PDF)

1．心血管疾患

日本内科学会雑誌, 2012, Vol.101(5), pp.1272-1277

2012

Volltextzugriff (PDF)

910-P: Relationship between Continuous Glucose Monitoring Metrics and Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

Diabetes (New York, N.Y.), 2020-06, Vol.69 (Supplement_1)

2020

Volltextzugriff (PDF)

An [alpha]-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes

Clinical and experimental medicine, 2010-06, Vol.10 (2), p.139

2010

Volltextzugriff (PDF)

Abstract 12375: Vascular Inflammation Evaluated by 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography is Associated With Endothelial Dysfunction

Circulation (New York, N.Y.), 2014-11, Vol.130 (suppl_2)

2014

Volltextzugriff (PDF)

Abstract 9844: Endothelial Function is Impaired in Subjects With Increased Ratio of Serum Levels of AGEs to Soluble Form of RAGE

Circulation (New York, N.Y.), 2015-11, Vol.132 (Suppl_3 Suppl 3), p.A9844-A9844

2015

Volltextzugriff (PDF)

Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats

Drugs under experimental and clinical research, 2005, Vol.31 (4), p.155

2005

Volltextzugriff (PDF)

Activation of Receptor for Advanced Glycation End Products Induces Osteogenic Differentiation of Vascular Smooth Muscle Cells

Journal of Atherosclerosis and Thrombosis, 2011, Vol.18(8), pp.670-683

2011

Volltextzugriff (PDF)

Addition of aliskiren to angiotensin II receptor blockers ameliorates renal tubular injury and reduces intima media thickness of carotid artery in patients with diabetic nephropathy

International journal of cardiology, 2012-03, Vol.155 (2), p.294-296

2012

Volltextzugriff (PDF)

Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria

Journal of the renin-angiotensin-aldosterone system, 2012-03, Vol.13 (1), p.122-127

2012

Volltextzugriff (PDF)

Adiponectin is inversely associated with ratio of serum levels of AGEs to sRAGE and vascular inflammation

International journal of cardiology, 2012-07, Vol.158 (3), p.461-462

2012

Volltextzugriff (PDF)

Administration of Pigment Epithelium-Derived Factor Inhibits Left Ventricular Remodeling and Improves Cardiac Function in Rats with Acute Myocardial Infarction

The American journal of pathology, 2011-02, Vol.178 (2), p.591-598

2011

Volltextzugriff (PDF)

Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice

Brain research, 2007-09, Vol.1167, p.92-100

2007

Volltextzugriff (PDF)

Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats

Nephrology, dialysis, transplantation, 2009-05, Vol.24 (5), p.1397-1406

2009

Volltextzugriff (PDF)

Advanced Glycation End Product-induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Human-cultured Mesangial Cells

The Journal of biological chemistry, 2002-06, Vol.277 (23), p.20309-20315

2002

Volltextzugriff (PDF)

Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes

Molecular medicine (Cambridge, Mass.), 2015-10, Vol.21 Suppl 1 (S1), p.S32-S40

2015

Volltextzugriff (PDF)

Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques

Neuroscience letters, 2002-06, Vol.326 (2), p.117-120

2002

Volltextzugriff (PDF)

Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes

Cardiovascular & hematological agents in medicinal chemistry, 2007-07, Vol.5 (3), p.236

2007

Volltextzugriff (PDF)

Advanced glycation end products (AGEs) and diabetic vascular complications

Current diabetes reviews, 2005-01, Vol.1 (1), p.93

2005

Volltextzugriff (PDF)

Advanced glycation end products (AGEs) and their involvement in liver disease

Current pharmaceutical design, 2008-04, Vol.14 (10), p.969

2008

Volltextzugriff (PDF)

Advanced glycation end products (AGEs) and their receptor (RAGE) in health and disease

Current pharmaceutical design, 2008, Vol.14 (10), p.939

Yamagishi, Sho-ichi

2008

Volltextzugriff (PDF)

Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy

Current drug discovery technologies, 2006-03, Vol.3 (1), p.83

2006

Volltextzugriff (PDF)

Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy

Current pharmaceutical biotechnology, 2011-03, Vol.12 (3), p.362

2011

Volltextzugriff (PDF)

1 – 25 von 553

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(491)
Mit Volltextzugriff
(449)

Publikationsform

Artikel
(529)
Buchkapitel
(19)
Bücher
(3)
Berichte
(2)

Sprache

Englisch
(534)
Japanisch
(224)

Erscheinungsjahr

n.n

Thema

Science & Technology
(428)
Life Sciences & Biomedicine
(423)
Humans
(368)
Male
(178)
Animals
(174)
Female
(141)
Oxidative Stress
(120)
Middle Aged
(119)
Glycation End Products, Advanced - Metabolism
(108)
Cardiovascular System & Cardiology
(106)
Aged
(104)
Biological And Medical Sciences
(101)
Receptor For Advanced Glycation End Products
(93)
Medical Sciences
(91)
Diabetes
(89)
Pharmacology & Pharmacy
(83)
Ages
(78)
Cells, Cultured
(71)
Endocrinology & Metabolism
(70)
Rage
(69)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

1. Cardiovascular Disease

1. Cardiovascular Disease

1．心血管疾患

910-P: Relationship between Continuous Glucose Monitoring Metrics and Oxidative Stress in Patients with Type 2 Diabetes Mellitus: A Cross-Sectional Study

An [alpha]-glucosidase inhibitor, acarbose treatment decreases serum levels of glyceraldehyde-derived advanced glycation end products (AGEs) in patients with type 2 diabetes

Abstract 12375: Vascular Inflammation Evaluated by 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography is Associated With Endothelial Dysfunction

Abstract 9844: Endothelial Function is Impaired in Subjects With Increased Ratio of Serum Levels of AGEs to Soluble Form of RAGE

Acarbose, an alpha-glucosidase inhibitor, improves insulin resistance in fructose-fed rats

Activation of Receptor for Advanced Glycation End Products Induces Osteogenic Differentiation of Vascular Smooth Muscle Cells

Acute effects of statin on reduction of angiopoietin-like 2 and glyceraldehyde-derived advanced glycation end-products levels in patients with acute myocardial infarction: a message from SAMIT (Statin for Acute Myocardial Infarction Trial)

Addition of aliskiren to angiotensin II receptor blockers ameliorates renal tubular injury and reduces intima media thickness of carotid artery in patients with diabetic nephropathy

Addition of aliskiren to olmesartan ameliorates tubular injury in chronic kidney disease patients partly by reducing proteinuria

Adiponectin is inversely associated with ratio of serum levels of AGEs to sRAGE and vascular inflammation

Administration of Pigment Epithelium-Derived Factor Inhibits Left Ventricular Remodeling and Improves Cardiac Function in Rats with Acute Myocardial Infarction

Administration of pigment epithelium-derived factor (PEDF) inhibits cold injury-induced brain edema in mice

Administration of pigment epithelium-derived factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats

Advanced Glycation End Product-induced Apoptosis and Overexpression of Vascular Endothelial Growth Factor and Monocyte Chemoattractant Protein-1 in Human-cultured Mesangial Cells

Advanced Glycation End Products: A Molecular Target for Vascular Complications in Diabetes

Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeldt-Jakob disease with prion plaques

Advanced glycation end products (AGEs) and cardiovascular disease (CVD) in diabetes

Advanced glycation end products (AGEs) and diabetic vascular complications

Advanced glycation end products (AGEs) and their involvement in liver disease

Advanced glycation end products (AGEs) and their receptor (RAGE) in health and disease

Advanced glycation end products (AGEs) and their receptor (RAGE) system in diabetic retinopathy

Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy

Suchergebnisse filtern